Guide to Chiome Bioscience
Chiome Bioscience Inc. promotes a variety of business activities as a drug discovery and technology oriented venture, based on our own unique technology in this field. Chiome Bioscience supports R&D on antibody drugs, using the ADLib® system, our core technology. We do this through alliances with numerous drug discovery companies(e.g., pharmaceutical companies, biotech, etc. ).
• Chiome Bioscience provides a new type of added value to major pharmaceutical manufacturer companies through two activities
Features of the Business Model
Programs centered on the ADLib® system, a unique drug discovery platform technology
Chiome Bioscience reduces our clients’ development risks from the searching at the drug discovery phase to each step of the value chain leading to postmarketing. In Chiome Bioscience’s business model, we receive upfront costs, compensation for success (milestone), and royalty.
Our business model enables us to enter contracts with multiple major drug manufacturers
Chiome Bioscience realizes a wide variety of income opportunities through non-exclusive contracts tailored to the drug discovery strategies of a wide variety of clients. This includes entering alliance contracts with multiple companies and entering multiple alliance contracts with the same company for each different target antigen.
Non-exclusive licensing out of Chiome Bioscience’s unique drug discovery platform technology
Chiome Bioscience licenses the ADLib® system through our program for licensing our platform technology.
Chiome Bioscience performs in-house R&D and maintains an antibody drug discovery system
By continuously improving the ADLib® system, Chiome Bioscience maintains a system that will contribute to achieving the ultimate health care in the future. This will include developing a new generation of drugs for pandemic diseases and discovering complete made-to-order drugs.
Relationships with Partnering Institutions
Chiome Bioscience is not only entering contracts with drug discovery companies, but is also expanding its operations by partnering with academia to obtain new targets and to achieve technical innovation.
• Chiome Bioscience’s relationships institutions